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ABSTRACT 
Somatostatin (SRIF, somatotropin release inhibitory factor) is a ubiquitously 
expressed neuropeptide, interacting with cells via five SRIF receptor subtypes (sst.-sst.), 
belonging to the guanine nucleotide binding protein-coupled receptor (GPCR) superfamily. SRIF 
receptors have been well documented for their ability to inhibit cell proliferation and secretion in 
a variety of animal tissues. Over the past l S years, pre-clinical and clinical studies implicate that 
SRIF and SRIF analog therapy improve symptoms in patients suffering from rheumatoid arthritis 
(RA). In this study, we investigate SRIF's effects on intracellular signaling in the synovium, the 
cellular layer that lines synovial joints, using in vitro cultures of human synovial fibroblasts. 
Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of synovial isolated mRNA 
established the presence of sst, in these cells. The sst, receptor links somatostatin action to 
control of synovial intracellular signaling. We have examined SRIF effects on the synoviocyte 
extracellular regulated kinase pathway (ERK). Using phospho-specific antisera, we demonstrate 
that SRIF and SRIF analogs decrease phospho-ERK.1/2 levels, suggesting basal ERK.1/2 is 
upregulated in RA synoviocytes. SRIF also suppressed basal levels of activated Raf and 
MEKl/2, two upstream regulatory kinases ofERKl/2. Furthermore, SRIF suppressed 1NFa­ 
stimulated activation ofERK.112 in RA synoviocytes. We also observed that SRIF increases a 
sodium vanadate-sensitive intracellular protein phosphatase activity in RA synoviocytes, 
indicating a possible intracellular mechanism by which SRIF controls the phosphorylation status 
of the ERK.112 kinases. Fluorescent confocal scanning microscopy reveals that TNF-o. stimulated 
the localization of phospho-ERK.112 in the nuclei of RA synoviocytes, which was inhibited upon 
co-treatment with SRIF. Taken together our results demonstrate that SRIF regulates intracellular 
signaling in rheumatoid synoviocytes. 
Vll 
INTRODUCTION 
Rheumatoid arthritis (RA) is an inflammatory, autoimmune disease that affects 
multiple organ systems and is of unknown etiology. In the affected joint, the synovicoyte 
is a major cellular target of pro-inflammatory mediators. Synoviocyte dysfunction is 
characteristic of RA and is defined by unregulated cellular hypertrophy and hyperplasia. 
In addition to synovial activation, angiogenesis and leukocyte infiltration ultimately lead 
to joint deterioration and reduced life expectancy (O'Dell, 2004; Choy and Panayi, 2001). 
Current RA therapies are not curative, however the disease modifying anti-rheumatic 
drugs (DMARDS) alleviate many RA symptoms (O'Dell, 2004). Clearly, a better 
understanding of RA synovial signal transduction would prove useful in developing long­ 
term therapies that preserve synovial integrity while suppressing the chronic 
inflammation. 
Although the initial immune trigger is unknown, CD4+ T-lymphocyte activation 
is an early event in RA pathology. Consequently, activated immune cells interact with 
the synovium and secrete pro-inflammatory cytokines. The synovium is comprised of 
both type A macrophage-like synoviocytes and type B fibroblast-like synoviocytes. 
Together with infiltrating T-lymphocytes, these three cell types dominate the RA 
synovial joint and are believed to mediate RA pathophysiology via intercellular signaling 
(Tran, et al., 2005). Immune cytokine release includes interleukins-I and -6 (IL-1, IL-6) 
1 
and tumor necrosis factor alpha (TNF-a), all of which initiate and promote synovial 
cytokine production and release (Choy and Panayi, 2001). TNF-a and IL-1� are the 
dominant pro-inflammatory mediators ofthis cytokine feedback loop which promotes the 
formation of an inflamed cellular pannus that induces chronic and aggressive joint 
destruction (Paran and Paran, 2003). 
The body's endogenous hormones and peptides regulate a spectrum of immune 
events (Krantic, 2001 ). For example, vasoactive intestinal peptide (VIP), originally 
identified as a vasodilator, has documented anti-inflammatory effects in several 
inflammatory diseases including septic shock syndrome, Crohn's disease, and arthritis, 
mimicking a Th2 cytokine (Pozo and Delgado, 2004). Substance P, a peptide 
neurotransmitter involved in pain transmission and contraction of intestinal smooth 
muscle, plays a role in neuroinflammation and has been indicated as a mediator of 
multiple sclerosis pathophysiology (Reinke and Fabry, 2006). Somatostatin (SRIF) 
modulates endothelial inflammation and immune cell recruitment, hallmark events in 
coronary artery disease (Badway and Blake, 2005). Somatostatin controls a host of 
systemic activities related to cell proliferation and secretion. SRIF was originally 
identified as a hypothalamic neurohormone that inhibits the release of growth hormone 
(GH, somatotropin) from the adenohypophysis (Brazeau, et al., 1973). Since then, SRlF 
has been found to control a spectrum of physiological functions, including the secretion 
of glucagon, insulin, thyroid stimulating hormone, and gastric acid, as well as the 
proliferation of normal and tumor cells (Dasgupta, 2004; Guillermet-Guibert, et al., 
2005). Indeed, SRlF has shown clinical utility in controlling the inappropriate 
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hypersecretion of growth hormone, hallmark of acromegaly (Melmed et al., 2005). Due 
to its extensive involvement in regulating cellular secretion, a role for SRIF in chronic 
inflammatory conditions has been proposed. 
SRIF peptides SRIF-28 and SRIF-14 are the predominant isoforms found in 
mammals (Reichlin, 1983), and are produced in the gut, CNS, and by tumor cells in a 
cell-specific manner (Patel, 1999). Cortistatin, a recently discovered member of the SRIF 
peptide family, appears to exhibit a discrete localization, while exhibiting a receptor 
binding pattern similar to the SR.IF peptides (Fukusumi, et al., 1997; Dalm, et al., 2003; 
de Lecea, 2005). The regional distribution of mature SR.IF peptides differ: SRIF-14 is 
widespread throughout the CNS and peripheral tissues while SRIF-28 is localized to the 
gut and cortistatin to the immune system (Reisine and Bell, 1995a; de Lecea, 2005). 
Both SRIF-14 and -28 originate from a single-gene product, a 1 1 6  amino acid prepro­ 
somatostatin that is cleaved into its aforementioned active counterparts, SRIF-28 
containing 14 additional residues at the amino terminus. Cortistatin is derived from a 
separate gene product, with a tissue-specific expression pattern (Dalm, et al., 2003). The 
SRIF family of peptides exhibits a unique FWKT binding domain that is preserved in a �­ 
tum configuration by an internal disulfide linkage (Patel and Reichlin, 1979). This 
binding domain is critical for receptor recognition (reviewed in ten Bokum, et al., 2000), 
and is exploited in the design and use of biologically active peptidomimetics (Blake, et 
al., 2004; Vaysse, et al., 2005). 
SRIF initiates its physiologic effects by ligating a family of highly homologous, 
heterotrimeric guanine nucleotide binding protein (G protein) coupled receptors (GPCRs) 
3 
designated sst.-sst-, including the splice variants sstzA and sst28• The SRIF receptor 
subtypes exhibit a distinct yet overlapping expression in tissues (Reisine and Bell, l 995b; 
Krantic, 2001 ). SRIF receptors primarily couple to the inhibitory G, and G0 proteins, 
which when activated, reduce cellular responsiveness (Hoyer, et al., 1995), however the 
downstream signaling mechanisms that predicate the physiologic response are both tissue 
and receptor subtype specific. (Lahlou, et al., 2004). 
SRIF receptor subtype sst
2 
is expressed in the synovium of patients with RA, 
identifying the synoviocytes as a cellular target for SRIF control (ten Bokum, et al., 
1999; Lu, et al., 2001). SRIF actions in vitro on RA synoviocytes have been observed; 
SRIF inhibits cytokine release and proliferation in RA synoviocytes (Takeba, et al., 
1997). Clinically, SRIF has proven useful in treating RA. For instance, intra-articular 
administration of SRIF-14 proves analgesic in RA patients and reduces the synovial 
pannus thickness, as assessed by ultrasound (Fioravanti, et al., 1995; Coari, et al., 1995; 
reviewed in Paran and Paran, 2003). Synthetic, receptor subtype-selective SRIF analogs 
have proven especially effective (Matucci-Cerinic, et al., 1992; reviewed in Paran and 
Paran, 2003), and recently intra-muscular injections of a highly selective sst, analog, 
octreotide, was beneficial in patients with DMARD refractory RA. (Paran, et al., 2001). 
Thus, SRIF and its analogs have proven therapeutic benefits in preclinical and clinical 
RA studies, thereby providing a rationale for studying SRIF cellular actions in RA. Our 
current knowledge of SRIF actions in RA is limited and relevant intracellular signaling 
pathways remain unknown. However, a number of cellular targets and mechanisms exist 
for SRIF actions in RA. 
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A spectrum of immune cell-derived cytokines has been implicated in RA 
initiation and progression, although the pro-inflammatory cytokine, TNF-u, is thought to ·  
be a major contributor to prolonged RA pathogenesis (Feldmann, et al., 2005). Clinical 
studies have demonstrated the utility of anti-TNF-u therapies (Feldmann, et al.; Genta, et 
al., 2006). In the current study we address the possible therapeutic role of SRIF and 
SRIF analogs in modulating TNF-a effects on the synovium. The canonical pathway for 
1NF-a up-regulation of the mitogen-activated protein kinase (MAPK) family involves 
members of the extracellular regulated kinase (ERK), c-Jun terminal kinases (JNK.), and 
p38 MAPK kinase families (Sweeney and Firestein, 2004 ). Of particular interest in the 
present study is the ERK.1/2 signaling pathway in which TNF-u activates the RA 
synovium (Schett, et al., 2000). ERK.1/2 activation has been implicated in the control of 
cell proliferation, apoptosis, cytokine expression, and matrix metalloproteinase 
production (Firestein, 2004). ERK.1/2 participates in a kinase cascade, and is active when 
phosphorylated by its upstream regulator, MEKl/2 (Figure 1 ). Phosphorylated ERK.1/2 
dimerizes and localizes to the cell nucleus where it serves to activate transcription, 
targeting transcription factors such as Elk-I and c-myc, ultimately controlling cell cycle 
progression (Murga, et al., 1999). Additionally, ERK.1/2 activation is required for MMP- 
1 ,  IL-6, IL-8, COX-2, and PGE gene expression in synovial fibroblasts, which may serve 
as pro-inflammatory mediators (Crofford, et al., 2005; Pillinger, et al., 2003; Neff, et al., 
2003). Previous studies have shown that the SRIF receptors control MAPK activity 
(reviewed in Vaysse, et al., 2005), for example, the down regulation of protein kinases 
such as Raf(MAPKKK), MEKl/2 (MAPKK), and ERK.1/2 (MAPK) is accomplished via 
5 
Figure 1. Linear cascade of the ERKl/2 MAPKpathway. Raf (MAPKKK) is a 
serine/threonine (Sff) kinase that activates MEKl/2 (MAPKK) by phosphorylating 
two specific serine residues (S2 l 7 /221 ). MEKl/2 is a dual specificity kinase that 
activates ERKI/2 (MAPK) by phosphorylating both a tyrosine and a threonine residue 
(T202/Y204). ERKI/2 itself is a srr kinase that targets both cytosolic and nuclear 
substrates. Upon phosphorylation, the two isoforms heterodimerize and enter the 
nucleus to phosphorylate and activate a host of transcription factors, thus regulating 
gene expression. 
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SRIF-induced phosphotyrosine phosphatases in sst. transfected Chinese hamster ovary 
(CHO) cells (Florio, et al., 1999). However, the direct molecular connection between the 
sst, receptor and the ERK.1/2 pathway has yet to be elucidated in RA synoviocytes. 
Since RA synoviocytes express a molecular target for SRIF, and SRIF peptides 
and analogs have been proven to regulate ERK.1/2 in other cell models, we studied the 
role of SRIF and an sst2 subtype-specific analog, L-779,976, on cultured RA 
synoviocytes. Our data reveal that SRIF acts through the endogenously expressed sst, 
receptor to regulate RA synovial activated MAPK pathway proteins, possibly through the 
control of protein tyrosine phosphatase activity. The current study identifies a novel 
strategy to control ERK.112-mediated inflammatory responses in the rheumatic synovium. 
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MATERIALS AND METHODS 
Cell Culture 
A commercial human fibroblast-like synoviocyte line (HFLS) was obtained from 
Cell Applications, Inc (CA). Additional primary synovial cell lines were isolated from 
surgical discard tissue obtained from the National Disease Research Interchange (NORI; 
Philadelphia, PA). Protocols used in obtaining NDRI surgical discard specimens were 
reviewed by the Institutional Review Board of Seton Hall University and categorized as 
exempt by the lRB. Surgical discard tissue was minced, digested with lmg/ml 
collagenase in serum-free media for 2 hat 37°C, and filter through a nylon mesh. The 
HFLS cells were cultured in T-75cm2 flasks and 24-well cell culture dishes purchased 
from Corning (Corning, NY) in Dulbecco's modified Eagle's medium, DMEM, (with 
GlutaMAXrn, high glucose, 1 lOmg L-1 sodium pyruvate and pyridoxine-HCL, 
lnvitrogen; Carlsbad, CA) containing 100 U ml" of penicillin, lOOµg mr1 streptomycin, 
250ng mr1 of amphotericin B, and 10% fetal calf serum and incubated at 37°C in a 
humidified atmosphere of 5% C02, 95% air. The cell cultures were passaged at 75% 
confluence, and given 48 hours to recover prior to experimentation. 
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mRNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR) 
Synovial mRNA was isolated using the MicroFast-Track™ 2.0 mRNA Isolation 
kit (Invitrogen Life Technologies, CA). 
Isolated synovial mRNA was reverse transcribed and amplified via polymerase 
chain reaction with the Superscript One-Step RT-PCR system (Invitrogen Life 
Technologies, CA). Thirty cycles of PCR [94°C, 30 s; 58°, 30 s; 72°C, 2 m] were 
performed following a reverse transcriptase step at 50° for 30 m, and a final elongation 
step at 72°C for 5 m. The primer sets used are: sstj-f = gcaacatgctcatgcc, sstj -r = 
gcgttatccgtccagg, sstj-f = agagccgtactatgacctga, sstj-r = agccactcggattccagag,(Invitrogen 
Life Technologies, CA) sstj-f = tcatctgcctctgctacctgc, sstj-r = gagcccaaagaaggcaggct, 
ssta-f= catggtcgctatccagtgca, ssta-r = gtgagacagaagacgctggtgaacat, ssty-f = 
gctcctggtgttcgcggacgt, ssty-r = gaggatgaccacgaagaagtagagg (Integrated DNA 
Technologies, Coralville, IA). The final reaction volume was 50µ1 in lX Reaction Mix 
buffer containing RT/Platinum Taq Mix, 1 OnM each forward and reverse primers, and 
template mRNA. Thermal cycling was performed using a Perkin Elmer Thermal Cycler 
9600 (Perkin Elmer, MA). Sst full-length cDNA clones were used as positive controls 
for each primer pair. 
RT-PCR products were resolved on 1.25% agarose gel in lx TAE buffer 
(Invitrogen Life Technologies, CA) and stained with ethidium bromide (I Oµg/ml). DNA 
products were visualized using a lN transilluminator (lNP, Inc., CA), and photo images 
were obtained with both a 35 mm Polaroid camera and digital images were captured with 
Alphalmager 3 .3D (San Leandro, CA) computer software. 
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-P AGE) and Western 
blotting 
Synoviocytes were cultured in 24-well plates with complete media for 48 h and 
then starved in serum-free media for 24 h in order to establish basal cell activity. The 
cultured cells were then incubated in the presence or absence of l OOnM SRlF-14 and L- 
779 ,976 in serum-free media for 15  min at 3TC. SRlF-14 was purchased from Peninsula 
Labs (Belmont, CA). L-779,976 was provided through a Materials Transfer Agreement 
between Seton Hall University and Merck & Co, Inc (Rahway, NJ). Following 
treatment, synoviocytes were lysed using IX NuP AGE LDS sample buffer (Invitrogen 
Life Technologies, CA). Cell lysates were sonicated and heated to 70°C for l O min, 
resolved on NuPAGE 10% Bis-Tris gels (Invitrogen Life Technologies, CA), 
electroblotted onto polyvinyldifluoride (PVDF) membranes and treated for 45 min in a 
blocking buffer containing 5% (w/v) non-fat dehydrated milk. Phospho-ERK.1/2 was 
then immunodetected with a 1 :  1000 dilution of affinity purified phospho-ERK.1/2 
antisera (Cell Signaling Technology, MA). The membrane was then incubated for 1 hour 
in a 1 :2000 dilution of a horseradish peroxidase-conjugated secondary antibody and the 
retained immunoreactivity detected using ECL chemiluminescence, according to the 
manufacturer's instructions (Amersham, NJ). The resulting autoradiograph was scanned 
and densitometric analysis was performed with NIH ImageJ and quantified using 
GraphPad Prism 4.0 (GraphPad Software, CA). 
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Protein tyrosine phosphatase assay 
Synovial fibroblast cultures were incubated in the presence or absence of 1 OOnM 
SRIF-14 (Peninsula Labs, Belmont, CA) for 15  min. Cell cultures were washed in PBS 
and then lysed in a 50mM HEPES buffer containing 0.5% Triton X-100, 10% glycerol 
(GibcoBRL), 2.5µM pepstatin A, 12.5µM leupeptin, 12.5µM aprotinin, 12.5µM 
bacitracin, and 200nM polymethylsulfonyl fluoride. Lysates were then centrifuged at 
13,500 x g for 15 min at 6°C and the supernatant retained. 
Protein phosphatase assays were performed in a 96 well plate (Corning, Corning, 
NY) as described (Badway et al., 2004). Briefly, synovial cell membranes were 
incubated with 50µM of the fluorescent phosphatase substrate, 6,8-difluoro-4- 
methylumberiferyll phosphate (DiF-MUP; Molecular Probes, OR; Gee et al., 1999) up to 
30 min at 37"C with intermittent mixing in a CytoFluor Series 4000 fluorescent plate 
reader (Applied Biosystems, CA). Fluorescence was detected using 360nm excitation 
and 460nm emission filters. Replicate parallel assays were conducted in the presence of 
1 OµM Na3 V04, an inhibitor of tyrosine phosphatase activity or 10 mM phosphatase 
inhibitor cocktail (Sigma, St Louis, MO), a commercially available inhibitor cocktail for 
serine/threonine phosphatases. The resulting data were analyzed with GraphPad Prism 
4.0 as described (Badway et al., 2004). 
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Fluorescence confocal scanning microscopy 
Synoviocytes were cultured on 4-well, 1 .8 cm2/well glass chamber culture slides 
(LabTek) with complete media (DMEM) for 48 h, then cultured in serum-free media for 
24 h, and then incubated in the presence or absence of lOOnM SRIF-14 plus or minus 
lOng/ml TNFa for 15 min at 3TC. The cell monolayers were then fixed in 4% 
paraformaldehyde, rinsed extensively in PBS and then incubated with phospho-ERK.1/2 
antisera ( 1 :  1000) in 1 % normal goat serum (Vector Laboratories, Burlingame, CA). 
Fluorescein (Vector Laboratories, CA) was used as the secondary detection antibody 
(fluorescein) and the incubation was carried out in 1 % normal goat serum. After 
extensive washing, the slides were prepared in Vectashield (Vector Laboratories, CA). 
Confocal fluorescent microscopy and digital image capture were performed with an 
Olympus Fluoview™ FVlOOO Confocal Microscope (Olympus, USA) and Olympus 
Fluoview FVlO-ASW Version 1 .3a software (Olympus, USA); the fluorescein 
conjugated immunoreactivity was excited at 485nm and the emitted at 530nm and was 
digitally captured. 
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RESULTS 
Identification of ssh on synovial fibroblasts via RT-PCR 
RT-PCR was performed, using SRIF receptor subtype specific oligonucleotide 
primer pairs to establish a potential target for SRIF interaction. Figure 2A demonstrates 
the ability of five SRIF receptor subtype-specific oligonucleotide primer pairs to amplify 
cloned cDNAs of sst1_5. Figures 2B-2D summarizes our findings on several synovial cell 
cultures. We demonstrate that ssh is present and appears as a 600 base pair amplified 
product in three different RA synovial tissues, while sst, 1, 3, 4, and 5 are absent. Our 
data corresponds with literature identifying sst2 on RA synovium (ten Bokum, et al., 
1999; Lu, et al., 2001 ), however differs from a group who have reported the presence of 
sst, in addition to sst, in synovial fibroblasts (Takeba, et al., 1997). 
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Figure 2. RT-PCR reveals sst; on synovial fibroblasts. A. PCR amplification of 
human cDNA clones for sstj., was performed to ensure that the SRIF subtype specific 
oligonucleotide primer pairs were capable of amplifying their target sequence. B. RT­ 
PCR amplification of total RA synovial mRNA (Cell Applications). C-D. Two 
different RA synovial surgical tissue samples amplified with SRIF receptor subtype 
specific oligonucleotide primer pairs (NDRI). 
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Western Blot detection of phosphorylated ERK.1/2 in RA synoviocytes 
MAPKs (mitogen activated protein kinases) regulate gene expression, cell 
proliferation, cell survival and death, and cell motility in mammalian models (Chang and 
Karin, 2001). ERK.1/2 (extracellular regulated kinases -1 and -2) are examples of these 
kinases that are expressed and activated in the RA synovium (Schett, et al., 2000). We 
assessed the activation ofERK.112 with phospho-specific antiserum via Western blotting 
experiments in response to SRIF and SRIF analog treatment. 
We reveal the ability of lOOnM SRIF to reduce phospho-ERK.1/2 by 34 ± 4% 
from basal levels in RA synoviocytes (Figure 3, *p<0.05 control versus SRIF treated). 
Furthermore, the sst, selective SRIF analog, L-779,976, reduced phospho-ERK.1/2 by 
46±7% from basal levels in RA synoviocytes (Figure 3, **p<0.01 control versus L- 
779,976 treated). 
Another MAPK protein, p38, has been indicated as a possible target for RA 
therapy (Peifer, et al., 2006). We saw no difference in active p38 levels between control 
and SRIF treated RA synoviocytes via Western blotting (data not shown). Furthermore, 
to ensure the effects of SRIF are mediated through the ERK.112 pathway, we used 
phospho-specific Raf and MEKl/2 antisera to assess the levels of activated upstream 
regulators ofERK.1/2. We found that acute SRIF reduced phospho-Raf'by 13±5% and 
phospho-MEKl/2 by 48±5% from basal levels in RA synoviocytes (Figure 4, p>0.05, 
and **p<0.01 control versus SRIF treated for phospho- Raf, and MEKl/2, respectively). 
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SRIF and L-779,976 reduce phospho-ERKl/2 in RAsynoviocytes 
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Figure 3. SRIF-14 and L-779,976 reduce phosphorylated ERKJ/2.from basal levels 
in RA HFLS. Parallel cultures of RA HFLS cells were cultured in serum-free basal 
medium for 24 hand then incubated in the presence or absence of 100 nM SRIF-14 or 
L-779,976 for 15  min at 37°C. Cell lysates were prepared and resolved on NuPAGE 
10% Bis-Tris gels, electroblotted, and incubated overnight with a 1 :  1000 dilution of 
an antiphospho-ERKl/2 antibody (Cell Signaling, Beverly, MA). Immunoreactivity 
was detected using a horseradish peroxidase-conjugated anti-rabbit second antibody in 
conjunction with chemiluminescence. Autoradiographs were quantified using NIH 
ImageJ software and data the were analyzed using Graphpad Prism 4.0. SRIF and L- 
779,976 data were normalized and analyzed compared to control; Student t-test shows 
these results are significantly different: C vs S, P = 0.0011 , C vs L, P = 0.0059, error 
bars represent plus the standard error of the mean ( +SEM). Data for SRIF and L- 
779,976 are not significantly different, C vs L, P = 0.2562). The inset shows a 
representative autoradiograph from six replicates in which C, S, and L refer to control, 
SRIF, and L-779,976, respectively. 
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SRIF reduces upstream activators ofERKl/2 
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Figure 4. SRIF-14 reduces phosphorylated Raf and MEKJ/2, from basal levels in RA 
HFLS. Parallel cultures of RA HFLS cells were cultured in serum-free basal medium 
for 24 h and then incubated in the presence or absence of 100 nM SRIF-14 for 15 min 
at 37°C. Cell lysates were immunoblotted with phospho-specific Raf and MEKl/2 
antisera similar! y to the protocol outlined in Figure 3 .  Autoradiographs were 
quantified using NIH ImageJ software and data was analyzed using Graphpad Prism 
4.0. SRIF data were normalized and analyzed compared to control. Student t-test 
shows phospho-Raf data are not significantly different from control: C vs S, P = 
0.1202; the error bars represent +SEM. Phospho-MEKl/2 are statistically significant: 
C vs S, P = 0.0075; the error bars represent +SEM. This experiment was performed in 
duplicate. 
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Determination of membrane phosphoprotein tyrosine phosphatase activity 
SRIF controls several intracellular phosphotyrosine phosphatases, thereby 
providing a basis for SRIF's well documented effects on cell proliferation (Patel, 1999). 
We investigated the effects of SRIF and L- 779 ,976 on the RA synoviocyte tyrosine 
phosphatase activity. We utilized DiF-MUP as a synthetic fluorescent phosphatase 
substrate, in conjunction with sodium vanadate which selectively inhibits protein tyrosine 
phosphatase activity. In particular, we investigated phosphatase activity in both the 
membrane and in soluble lysates of RA synoviocytes. SRIF increased phosphatase 
activity in RA synoviocytes by 3-fold from basal levels (*p<0.05, C vs S) and this affect 
was abolished by sodium vanadate (Figure 5). SRIF did not affect soluble phosphatase 
activity (data not shown) . 
1 8  
Somatostati n increases membrane phosphotyrosi ne phosphatase activity 
SOµMDiFMUP 
--SRIF 
-+SRIF 
SOµM DiFMUP & H\.1M N33V04 
Figure 5. SRIF activates phosphatase activity in RA HFLS. RA synoviocytes (Cell 
Applications, Inc., CA) were grown to 75% confluence on T-75 cm- flasks and were 
incubated in the absence or presence of 100 nM SRIF-14, and 10 µM Na3 V04• 
Membranes were prepared in 50 mM HEPES, 0.5% Triton X-100, 10% glycerol, 2.5 
µM pepstatin A, 12.5 µM leupeptin, 12.5 µM aprotinin, 12.5 µM bacitracin and 200 
nM PMSF. The suspension was incubated with 50 µM fluorescent phosphatase 
substrate (DiF-MUP; Gee et al., 1999) for 10 min at 37°C with intermittent mixing in 
a CytoFluor 4000 fluorescent plate reader (Applied Biosystems). Student's T-test 
shows statististical difference, P = 0.0103, Control vs SRIF, 50µM DiFMUP. 
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Western Blot detection of phosphorylated ERKl/2 in synovial tissue samples 
To further our study, we investigated the levels ofERKl/2 via immunoblotting in 
tissues received from NDRI, presumed to be from RA patients. The RA synovial tissue 
samples were selected for study based on the patients' medical history (Table 1). The 
patient and primary cell lines created from these RA tissue samples were identified 
arbitrarily (RA2 & RA3). Prednisone, a glucocorticoid, and the nonsteriodal anti­ 
inflammatory drug (NSAID), Bextra were used to treat patient RA2, while Diclofinac 
(NSAID) and a disease modifying anti-rheumatic drug (DMARD) Azulfadine were used 
to treat patient RA3. In other RA tissues (RAl and RA4), it was unclear that these 
patients were in fact suffering from the disease because they were not prescribed typical 
RA medications (information not shown). 
We investigated SR.IF modulation of phospho-ERKl/2 in the RA3 synovial cell 
line in the absence or presence ofTNFu. Previously, we have shown that SRIF decreased 
phospho-ERKl/2 by 34±4% in a commercial RA cell line (Figure 3). Again, we 
demonstrate SRIF's ability to reduce phospho-ERKl/2 by 28±9% in RA3 synovial 
monolayers (Figure 6, p>0.05 control versus SRIF treated). TNFu increased phospho­ 
ERKl/2 by 128±53% in RA3 synoviocytes (Figure 6, p>0.05 control versus TNFu 
treated). Of particular interest was the ability of lOOnM SRIF to reduce TNFu-stimulated 
phospho-ERKl/2 to basal levels (Figure 6, p>0.05 TNFu treated versus TNFu + SRIF 
treated). 
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Cell Line Diagnosis Age Race Sex Height Weight Medications 
Duragesic Patch, Oxycodone, Valtrex, 
RA2 RA 67 Caucasian F 5' 2" 123 lbs Levoxyl, Prednisone, Bextra, 
Colestid, Folic Acid 
Tegretol, Klonapine, Prozac, 
RA3 RA 39 Caucasian F 5' 2" 1 17  lbs Azulfadine, Diclofinac, Prilosec, 
Topamax, Replax 
Table 1. RA synovial tissue donor information. Patient history appears in tabulated 
form; medical history and pharmacology were considered when selecting synovial 
tissues to study. Medications in bold and underlined font are utilized in treatment of 
patients with rheumatoid arthritis. The medications in italics may have been used as 
analgesics to control pain associated with RA. Because the donor retains anonymity, 
a medical consult was not possible. 
SRIF & 1NFa effects on phospho-ERKl/2 in RA synovial tissue 
Control TNiu SRIF TNlu + SRIF 
Figure 6. SRIF-14 reduces TNFa-induced ERKJ/2 phosphorylation in RA 
synoviocytes derived from tissue donors. Monolayer cultures from the RA3 tissue 
sample of RA synoviocytes were immunoblotted with phospho-ERKl/2 antiserum as 
outlined in Figure 3. Autoradiographs were quantified using NIH ImageJ software and 
data was analyzed using Graphpad Prism 4.0. Data were normalized and analyzed 
compared to control or TNFa treated; Student t-test shows that these results are not 
significantly different: C vs T, P = 0.0953; C vs S, P = 0.0949; C vs T +S, P = 0. 1891 ;  
T vs T +S, P = 0.2809, error bars represent +SEM. The inset shows a representative 
autoradiograph from three replicates in which C, T, S, and T +S refer to control, TNFa, 
SRIF, and TNFa+SRIF, respectively. 
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Fluorescence detection of phosphorylated ERK.1/2 in synovial tissue samples 
Confocal fluorescence microscopy was performed to visualize the location of 
phosphorylated ERK.1/2 in the RA3 synoviocyte. Cells were treated in the absence or 
presence of SRIF and TNF-a for 15 m. Under control conditions, phospho-ERK.1/2 did 
not accumulate in the nucleus (Figure 7 A). However, acute TNF-a treatment caused 
activation and movement ofERKl/2 into the nuclei of approximately 24% of the cell 
population. (Figure 7B, 7E). Acute SRIF treatment also promotes the recruitment of 
phosphorylated ERK.1/2 into the nuclei of a small population of cells (Figure 7C, 7E). 
However, these cells do not appear to hold the same morphology as the synovial 
fibroblasts. We have not yet identified the phenotype of these cells. Upon acute co­ 
treatment of SRIF and TNFa, phospho-ERK.1/2 does not accumulate in the nuclei of 
these cells (Figure 70). These results indicate that the tissue population is 
heterogeneous, and suggest only a portion of the population are transformed 
synoviocytes. 
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Figure 7. Fluorescence confocal scanning microscopy of synovial tissue. Monolayer 
cultures of synoviocytes from the RA3 tissue donor were treated in the absence or 
presence of SRIF (lOOnM) and TNFa (lOng/ml): A. Control, B. TNFa, C. SRIF, D. 
TNFa + SRIF. After treatments, the cells were fixed in 4% paraformaldehyde, probed 
with phospho-ERKl/2 antiserum, and detected with fluorescein secondary antibody, 
both in 1 % normal goat serum. Microscopy and digital photography were performed 
with an Olympus Fluoview TM FVlOOO Confocal Microscope, 485nm excitation, 
530nm emission. E. Representative bar graph showing the percentage of cells with 
activated ERKl/2 in the nucleus. 
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DISCUSSION 
Rheumatoid Arthritis (RA) is a debilitating autoimmune disease in which affected 
individuals suffer from decreased mobility due to bone and cartilage destruction. The 
initial immune trigger is unknown, however it is believed that synovial dysfunction plays 
a critical role in disease progression, as well as RA associated morbidity and mortality 
(Zvaifler and Firestein, 1994; Takeba, et al., 1997). Understanding the underlying signal 
transduction of the RA synoviocyte might prove critical in developing novel therapeutic 
treatments to retard the progression of the chronic disease. 
Mitogen activated protein kinases (MAPKs) are highly conserved intracellular 
signaling proteins that exist in several distinct families in vertebrates (Chang and Karin, 
2001 ). The MAPKs regulate a spectrum of cellular activity, including cell survival, 
proliferation and intercellular signaling. In the RA synoviocyte, MAPKs have been 
implicated in pro-inflammatory cytokine production and metalloproteinase production, 
cellular products that promote synovial dysfunction and joint destruction (Sweeney and 
Firestein, 2004). Since the RA synoviocyte is an active participant in the RA process, 
synovial targets that could mitigate or silence these inflammatory responses could prove 
useful in RA treatment. Several reports have recently appeared indicating that the 
ubiquitous neuropeptide, SRIF, might play a role in controlling RA synovial responses. 
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(reviewed in Paran and Paran, 2003). However, to date, no signal transduction 
mechanism for SRIF action in the synoviocyte has been proposed. 
In our initial studies we observed that the native peptide SRIF and the sst, subtype 
peptidomimetic, L-779,976, suppressed basal ERK.1/2 phosphorylation, suggesting that in 
the RA cells examined, there was an elevation of basal ERK.1/2 phosphorylation. This 
elevation of basal ERK.1/2 activity could be explained by the constant exposure of the 
synovium to pro-inflammatory cytokines in the RA joint. In several studies, SRIF has 
been implicated as a regulator ofMAPKs, specifically ERK.1/2. In other in vitro disease 
models, several protein tyrosine phosphatases have been proposed to mediate the SRIF 
effect (Badway and Blake, 2005; Vaysse et al., 2005). Interestingly, SRIF modulation of 
the ERK.1/2 MAPK pathway is both receptor subtype and cell specific, demonstrating the 
need to delineate among the receptor subtypes present in specific cell populations (Blake, 
et al., 2004; Lahlou, et al., 2004). 
In this study we have identified, via RT-PCR, the SRIF receptor subtype 2 (sst2) 
in cell cultures derived from human synovial tissue. In contrast with an earlier study, we 
were unable to detect sst, mRNA which had been previously reported to exist along with 
sst, in the synovium (Takeba, et al., 1997). Although both studies used synovium 
derived from the knee, Takeba and colleagues (Takeba, et al., 1997) also included 
synovial membrane from other body regions including the wrist. Since SRIF receptor 
expression is anatomically heterogeneous, the inclusion of the wrist synovium may have 
been responsible for the presence of sst, mRNA. Indeed, our control PCR amplifications 
indicated that the oligonucleotide pairs used for sst, amplification in this study were able 
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to amplify the human sst, cDNA and the correct PCR product size was obtained (Figure 
2A), suggesting that any sst, mRNA present would have been detected in our protocol. 
The synovial fibroblasts are known targets of pro-inflammatory cytokines, and 
upon activation may participate in the initiation and development of joint destruction 
(Davis, 2003). TNF-o. is a critical cytokine in the arthritic pro-inflammatory response and 
is considered a major therapeutic target in RA (Reimold, 2002). Takeba and colleagues 
reported that TNF-o. treatment up-regulated IL-6 and IL-8 cytokine expression and MMP 
production, both integral to RA development and pathogenesis (Takeba, et al., 1997). Of 
considerable interest, was also the observation that SRIF treatment was able to suppress 
these TNF-o. mediated increases, which included decreasing cellular mRNA levels for IL- 
6, IL-8, MMP-1, MMP-2 and MMP-9 (Takeba, et al., 1997). Takeba and colleagues 
(Takeba, et al., 1997) hypothesized that SRIF inhibition of the transcription factor, cyclic 
AMP response element binding protein (CREB), was responsible for this downregulation 
of synovial interleukin and MMP mRNA. The SRIF suppression of cyclic AMP 
production by adenylyl cyclase, and the corresponding inhibition of cyclic AMP­ 
dependent protein kinase (PKA) are hallmarks of SRIF action in all cells studied to date 
(Blake, et al., 2004). A corresponding decrease in CREB activation and migration to the 
cell nucleus would then be predicted, ifSRIF were controlling the synovial PKA 
signaling pathway. Indeed, a modest reduction in CREB was observed in the synovial 
cells that were co-treated with TNF-o. and SRIF, suggesting that SRIF may decrease the 
synovial intracellular cAMP levels. However, it is hard to reconcile the modest decrease 
in CREB nuclear transport observed by Takeba and colleagues (Takeba, et al., 1997) with 
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the almost complete ablation of the synovial IL-6, IL-8, and MMP mRNA that was also 
noted. Therefore, an additional intracellular signaling pathway must be controlled by 
SRIF in the RA synoviocytes. Our current results support this notion. 
In our study we utilize two SRIF ligands, SRIF-14, the most prevalent 
endogenous form of SRIF, and L-779,976, an sst, receptor subtype selective, 
nonpeptidyl, SRIF analog, to reveal SRIF modulation ofERK.1/2 via an sst, mediated 
pathway in RA synoviocytes. More specifically, SRIF reduced activated ERK.1/2 in 
these cells by 34 ± 4% while the synthetic analog, L-779,976, reduced ERK.1/2 
phosphorylation by 46±7% (Figure 3). There was no statistical difference between SRIF 
and L-779,976 treatments (Figure 3, p>0.05 S vs L). The phosphorylation state of 
ERK.1/2 parallels functional activity of this protein kinase family, with increasing 
phosphorylation correlating with increased ERK.1/2 activity (Chang and Karin, 2002). 
Reducing active ERK.1/2 levels in RA synoviocytes could suppress synovial hypertrophy, 
hyperplasia, and cytokine secretion, all of which are characteristic of a transformed 
synoviocyte (Davis, 2003). Our results (Figure 3) clearly indicate that SRIF treatment of 
the RA synoviocytes decreases the phosphorylation status of ERK.1/2 in these cells, 
suggesting an additional mechanism by which SRIF could suppress IL-6, IL-8, and MMP 
production in fibroblasts (Takeba, et al., 1997) 
It is not fully understood how SRIF receptor activation ends with ERK.1/2 in the 
nucleus. Tyrosine phosphorylation is a rare event in the cell, and could indicate a novel 
method by which to control ERK.1/2 activation in the synoviocyte. ERK.1/2 activation 
involves the reversible phosphorylation of a tyrosine and threonine, a process which is 
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reversed by a family of dual specificity protein phosphatases (Farooq and Zhou, 2004). 
To date, SRIF activity has not been shown to directly activate any of the known dual 
specificity protein phosphatases that regulate ERK.1/2 activity. Alternatively, SRIF has 
been shown to control ERK.1/2 through the upregulation of protein tyrosine phosphatase 
(PTP) activity, and the subsequent dephosphorylation and inhibition of the upstream 
activating kinases in the ERK.1/2 pathway (Vaysee, et al., 2005). At this time, the 
identity of this tyrosine phosphatase, controlling the ERK.1/2 pathway, is not known. 
Correspondingly, we observed an SRIF-induced suppression of Raf and MEKl/2 
phosphorylation, two upstream kinases regulators of ERK.1/2. Thus, we investigated 
whether SRIF could modulate tyrosine phosphatase activity within the RA synoviocyte. 
We used a fluorescent surrogate substrate for phosphorylated tyrosine, 6,8-difluoro-4- 
methylumberiferyll phosphate (DiF-MUP), which when used in conjunction with the 
tyrosine phosphatase inhibitor, sodium vanadate, provides a robust and reliable measure 
of protein tyrosine phosphatase activity (Badway, et al., 2004). We observed that in our 
DiF-MUP assay, SRIF increased PTP activity in the membranes derived from SRIF-14 
treated cells by approximately 3-fold (Figure 4). Co-incubation of the cell membranes 
with the tyrosine phosphatase inhibitor, sodium vanadate, completely abolished this 
activity, suggesting that tyrosine phosphatase activity was under SRIF control in the 
synoviocytes. It is unclear where these PTPs intercede the ERK.1/2 pathway in RA 
synoviocytes, however it can be hypothesized that membrane-associated proteins are the 
substrate of preference since SRIF did not affect soluble PTP activity in these RA 
synoviocytes ( data not shown). The inhibition of membrane associated tyrosine 
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phosphatase activity also suggests that the dual-specificity tyrosine phosphatases are 
unlikely to be the target of SRIF control in the RA synoviocytes, since the activity of the 
dual specificity phosphatases appears to be largely restricted to the cytosolic and nuclear 
compartments (Farooq and Zhou, 2004). 
Utilizing tissue procured from the National Disease Research Interchange 
(NDRI), we investigated activated ERK.112 levels in synoviocytes (RA3) cultured from 
an RA patient tissue sample. We found that this tissue responded to SRIF treatment 
comparatively to the commercial RA tissue in our initial studies. In fact, SRIF reduced 
levels ofphosphorylated ERK.112 by 28±9% in these cells from basal levels as 
determined by western blotting (Figure 6). Our data also support findings that TNF-a 
activates ERK.1/2 in the RA synovium (Figure 6; Lacey, et al., 2002). In intestinal 
epithelial cells, SRIF reduced both basal and TNF-a-induced secretion ofIL-8 and IL-IP, 
demonstrating its anti-inflammatory effect in this in vitro model (Chowers, et al., 2000; 
reviewed in Paran and Paran, 2003). We reveal that SRIF inhibits TNF-a-stimulated 
upregulation ofERK.1/2 in RA synoviocytes, suggesting SRIF's potential modulation of 
cytokine and pro-inflammatory mediator release via TNF-a attenuation. 
To further investigate and verify the previous immunoblotting experiments, we 
used fluorescence confocal scanning microscopy to visualize ERK.1/2 localization within 
the RA3 synovial fibroblasts. Our results reveal that TNF-a activates ERK.1/2 in a 
sample of the synovial population (Figure 7B). It appears that SRIF also activates a 
minute subset of the population, however these cells have different morphological 
features as compared to synovial fibroblasts (Figure 7C). Co-treatment of SRIF and 
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TNF-a had no effect on the nuclear localization of ERK.1/2, confirming SRIF's ability to 
inhibit TNFa-stimulated ERK.1/2 activation (Figure 7D). Interestingly, the entire cell 
population does not respond to TNFa stimulation, suggesting that this tissue is in fact a 
heterogeneous population of cells perhaps composed of diseased and non-diseased 
synoviocytes. We suggest that these tissues are not advanced or refractory RA tissues; 
our skepticism lies in the medical history of the patients. Since the early 90s, the gold­ 
standard for RA treatment has been methotrexate, which was not used to treat any of our 
four RA tissue donors (Table 1 ). Although some patients are not responsive to 
methotrexate, it is has been the dominant choice ofDMARDs because of its low-cost, 
effectiveness in retarding the disease, and tolerability (Choi, et al., 2000). 
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CONCLUSIONS 
In this study, we reveal a regulatory role of SRIF in a RA synoviocyte in vitro 
model, identifying a target, the sst2 receptor for SRIF intervention in the human synovial 
fibroblast. We have demonstrated that SRIF decreases ERK.1/2 levels in RA 
synoviocytes, suggesting that basal ERK.1/2 is upregulated in this tissue. Additionally, 
we have shown that the inhibition of ERK.1/2 in RA synoviocytes may be associated with 
SRIF-mediated up-regulation of protein tyrosine phosphatases. In tissue cultured from 
RA patients, we found that SRIF suppressed both basal and TNF-a-stimulated ERK.1/2 
levels, indicating SRIF's ability to attenuate TNF-a effects on RA synoviocytes. Further 
studies delineating the protein-protein interactions, under SRIF control, of the ERK.1/2 
MAPK pathway could provide new targets for RA therapy 
Future studies utilizing synovial tissue from true refractory RA patients could 
provide a more homogeneous cell population to study SRIF's effects on ERK.1/2 
activation. Additionally, treating normal and non-refractory RA synoviocytes with a 
cocktail of cytokines and chemokines in attempt to transform these cells, could provide 
insight into the differentiation process of an RA synoviocyte. This information could aid 
in developing novel therapies that target cytokine-mediated events in RA synoviocytes. 
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